Sales dependence on products related to hemodialysis
First written in FY2016. 17 of 36 entries say "Mitigated", first in FY2018-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026MitigatedAnnual report
「Sales of hemodialysis products were ¥7,815.602 million, down 2.1% year on year.」
Sales of hemodialysis products accounted for approximately 32.9% of consolidated net sales of ¥23,781.456 million, down from approximately 35.4% in the previous fiscal year. However, they remain a major component of sales. - 2026-05-15MitigatedResults
「人工透析類におきましては、7,815百万円（前年同期比2.1％減）となりました。」
人工透析類の売上高は減少し、連結売上高に占める比率も前期の約35.4％から約32.9％へ低下している。ただし、主要な売上構成である状況は続いている。 - FY2026-H1MitigatedAnnual report
「Sales of hemodialysis products were ¥4,053.937 million, up 0.8% year on year.」
Sales of hemodialysis products accounted for approximately 34.0% of consolidated net sales of ¥11,921.914 million. Although the sales concentration ratio declined from approximately 35.6% in the same period of the previous year, they remain a major component of sales. - FY2025WorsenedAnnual report
「Sales of hemodialysis products were ¥7,981.199 million, up 4.7% year on year.」
Sales of hemodialysis products accounted for approximately 35.4% of consolidated net sales of ¥22,553.238 million, up from approximately 34.9% in the previous fiscal year. The risk of sales concentration in core products increased slightly. - FY2024-Q3MitigatedAnnual report
「Sales of hemodialysis products were ¥5,979.074 million, up 2.1% year on year.」
Sales of hemodialysis products accounted for approximately 35.5% of consolidated net sales of ¥16,860.994 million, slightly down from approximately 35.6% in the same period of the previous year. They remain a major component of sales, but the sales concentration ratio narrowed year on year. - FY2024-Q2WorsenedAnnual report
「Sales of hemodialysis products were ¥3,859.045 million, up 4.2% year on year.」
Sales of hemodialysis products accounted for approximately 35.6% of consolidated net sales of ¥10,845.780 million, up from approximately 35.1% in the same period of the previous year. Sales became slightly more concentrated in hemodialysis-related products year on year. - FY2024-Q1WorsenedAnnual report
「Sales of hemodialysis products were ¥1,995.842 million, up 9.4% year on year.」
Sales of hemodialysis products accounted for approximately 36.0% of consolidated net sales of ¥5,549.918 million, up from approximately 34.5% in the same period of the previous year. The sales concentration ratio for hemodialysis-related products increased. - FY2023MitigatedAnnual report
「Sales of hemodialysis products were ¥7,526.040 million, up 3.6% year on year.」
Sales of hemodialysis products were ¥7,526.040 million, accounting for approximately 34.8% of consolidated net sales of ¥21,607.233 million. This was down from approximately 36.1% in the previous fiscal year. Although the sales concentration ratio narrowed, they remain a major component of sales. - FY2023-Q3MitigatedAnnual report
「Sales of hemodialysis products were ¥5,853.738 million, up 3.8% year on year.」
Sales of hemodialysis products accounted for approximately 35.6% of consolidated net sales of ¥16,448.251 million, down from approximately 36.3% in the same period of the previous year. Although the sales concentration ratio narrowed, they remain a major component of sales. - FY2023-Q2MitigatedAnnual report
「Sales of hemodialysis products were ¥3,703.804 million, down 0.2% year on year.」
Sales of hemodialysis products accounted for approximately 35.1% of consolidated net sales of ¥10,562.705 million, down from approximately 37.1% in the same period of the previous year. Although the sales concentration ratio narrowed, they remain a major component of sales. - FY2023-Q1MitigatedAnnual report
「Sales of hemodialysis products were ¥1,824.800 million, down 2.2% year on year.」
Sales of hemodialysis products accounted for approximately 34.5% of consolidated net sales of ¥5,294.456 million, down from approximately 37.7% in the same period of the previous year. Although the sales concentration ratio for hemodialysis-related products narrowed, they remain a major component of sales. - FY2022RestatedAnnual report
「The Group provides products in 3 categories: hemodialysis, indwelling venous needles, and intervention. In each category, core products account for a high proportion of sales. Accordingly, if the Group's core products were drawn into excessive price competition or otherwise forced to sell at lower prices, or if the products became obsolete and their competitiveness declined significantly, the Group's business and results could be affected.」
The risk continues to be presented as dependence on core products in each of the 3 categories, rather than as the previous concentration ratio for hemodialysis products. - FY2022-Q3MitigatedAnnual report
「Sales of hemodialysis products were ¥5,639.139 million, up 1.2% year on year.」
Sales of hemodialysis products accounted for approximately 36.3% of consolidated net sales of ¥15,534.928 million, down from approximately 37.1% in the previous quarter. Although the sales concentration ratio narrowed, it remains high. - FY2022-Q2WorsenedAnnual report
「Sales of hemodialysis products were ¥3,711.602 million, up 1.4% year on year.」
Sales of hemodialysis products accounted for approximately 37.1% of consolidated net sales of ¥10,008.392 million, up from approximately 35.7% in the same period of the previous year. Sales are becoming more concentrated in hemodialysis-related products. - FY2022-Q1MitigatedAnnual report
「Sales of hemodialysis products were ¥1,865.752 million, down 2.9% year on year.」
Sales of hemodialysis products accounted for approximately 37.7% of consolidated net sales of ¥4,946.691 million, down from approximately 40.3% in the same period of the previous year. Although the sales concentration ratio narrowed year on year, it remains high. - FY2021WorsenedAnnual report
「Sales by product category, which is the Group's product classification, were as follows. Sales of hemodialysis products were ¥7,078.822 million, down 0.2% year on year. …Consolidated results for the fiscal year were net sales of ¥19,312.663 million, down 2.9% year on year.」
Sales of hemodialysis products accounted for approximately 36.7% of consolidated net sales, allowing the dependence ratio, which had not been disclosed for the previous year, to be confirmed numerically again. The risk of sales concentration in core products continues. - FY2021-Q3WorsenedAnnual report
「Sales of hemodialysis products were ¥5,570.715 million, up 0.4% year on year.」
Sales of hemodialysis products accounted for approximately 37.5% of consolidated net sales of ¥14,870.612 million, up from approximately 35.8% in the same period of the previous year. Sales became more concentrated in hemodialysis-related products year on year. - FY2021-Q2WorsenedAnnual report
「As a result, consolidated results for the first six months of the fiscal year were net sales of ¥9,623.957 million, down 3.8% year on year. Sales of hemodialysis products were ¥3,661.482 million, up 2.4% year on year.」
Sales of hemodialysis products accounted for approximately 38.0% of consolidated net sales, up from approximately 35.7% in the same period of the previous year. Sales are becoming more concentrated in hemodialysis-related products. - FY2021-Q1WorsenedAnnual report
「During the first quarter of the fiscal year, consolidated results were net sales of ¥4,769.090 million, down 4.3% year on year, operating income of ¥959.287 million, down 15.5%, ordinary income of ¥997.113 million, down 14.2%, and net income attributable to owners of the parent of ¥485.694 million, down 17.3%. Sales of hemodialysis products were ¥1,920.986 million, up 7.1% year on year.」
Sales of hemodialysis products accounted for approximately 40.3% of consolidated net sales, up from approximately 35.7% in the same period of the previous year. The figures confirm that sales are becoming more concentrated in hemodialysis-related products. - FY2020ReframedAnnual report
「The Group provides products in 3 categories: hemodialysis, indwelling venous needles (anesthesia), and intervention (angiography). In each category, core products account for a high proportion of sales.」
The presentation has been changed from the conventional expression showing the sales ratio of hemodialysis-related products to a description of the Group's dependence on core products in each of the 3 categories. This filing does not disclose the specific dependence ratio for hemodialysis products. - FY2020-Q3MitigatedAnnual report
「Sales of hemodialysis-related products amounted to ¥5,548,559 thousand, up 7.4% year on year.」
Sales of hemodialysis-related products accounted for approximately 35.8% of consolidated net sales of ¥15,486,957 thousand, down from approximately 36.5% in the same period of the previous year. The sales concentration ratio decreased year on year, but remains high. - FY2020-Q2MitigatedAnnual report
「Sales of hemodialysis-related products amounted to ¥3,576,439 thousand, up 8.8% year on year.」
Sales of hemodialysis-related products accounted for approximately 35.7% of consolidated net sales of ¥10,007,872 thousand, down from approximately 36.1% in the same period of the previous year. The sales concentration ratio decreased year on year, but remains high. - FY2020-Q1WorsenedAnnual report
「Sales of hemodialysis-related products amounted to ¥1,793,103 thousand, up 9.0% year on year.」
Sales of hemodialysis-related products and the year-on-year change were presented, with the products accounting for approximately 36.0% of consolidated net sales. - FY2020-Q1WorsenedAnnual report
「Sales of hemodialysis-related products amounted to ¥1,793,103 thousand, up 9.0% year on year.」
Sales of hemodialysis-related products accounted for approximately 36.0% of consolidated net sales of ¥4,981,432 thousand, up from approximately 35.7% in the same period of the previous year, indicating a slight increase in sales concentration. Dependence on hemodialysis-related products continues. - FY2019-Q3MitigatedAnnual report
「Sales of hemodialysis-related products amounted to ¥5,164,351 thousand, up 4.8% year on year.」
Sales of hemodialysis-related products accounted for approximately 36.3% of consolidated net sales of ¥14,238,106 thousand, down from approximately 36.5% in the same period of the previous year. The sales concentration ratio decreased year on year, but remains high. - FY2019-Q2WorsenedAnnual report
「Sales of hemodialysis-related products amounted to ¥3,287,657 thousand, up 5.6% year on year.」
Sales of hemodialysis-related products accounted for approximately 36.3% of consolidated net sales of ¥9,069,645 thousand, up from approximately 36.1% in the same period of the previous year. The sales concentration ratio increased slightly year on year, and the dependence risk has worsened. - FY2019-Q1WorsenedAnnual report
「Sales of hemodialysis-related products amounted to ¥1,645,185 thousand, up 6.1% year on year.」
Sales of hemodialysis-related products accounted for approximately 37.0% of consolidated net sales of ¥4,448,424 thousand, up from approximately 35.7% in the same period of the previous year, indicating increased sales concentration. - FY2018MitigatedAnnual report
「Sales of hemodialysis-related products, centered on the core Happy Cass product, remained high in the fiscal year ended March 2018, at ¥6,358,683 thousand, accounting for 36.5% of consolidated net sales.」
The concentration of sales in hemodialysis-related products decreased from 36.8% in the previous fiscal year to 36.5%, but remained at a high level. - FY2018-Q3MitigatedAnnual report
「Sales of hemodialysis-related products amounted to ¥4,925,635 thousand, up 2.1% year on year.」
Sales of hemodialysis-related products accounted for approximately 36.5% of consolidated net sales of ¥13,488,941 thousand, down from approximately 37.4% in the same period of the previous year. The sales concentration ratio decreased year on year, but remains high. - FY2018-Q2MitigatedAnnual report
「Sales of hemodialysis-related products amounted to ¥3,114,713 thousand, down 1.1% year on year.」
Sales of hemodialysis-related products accounted for approximately 36.1% of consolidated net sales of ¥8,630,516 thousand, down from approximately 37.5% in the same period of the previous year, reducing the sales concentration risk year on year. However, they still account for a high proportion. - FY2018-Q1MitigatedAnnual report
「Sales of hemodialysis-related products amounted to ¥1,550,594 thousand, down 1.9% year on year.」
Sales of hemodialysis-related products declined 1.9% year on year, accounting for approximately 35.7% of consolidated net sales, down from approximately 37.8% in the same period of the previous year. However, sales remain concentrated. - FY2017WorsenedAnnual report
「Sales of hemodialysis-related products, centered on the core Happy Cass product, remained high in the fiscal year ended March 2017, at ¥6,203,840 thousand, accounting for 36.8% of consolidated net sales.」
The concentration of sales in hemodialysis-related products increased from 36.6% in the previous fiscal year to 36.8%. - FY2017-Q3RestatedAnnual report
「Sales of hemodialysis-related products amounted to ¥4,824,126 thousand, up 9.3% year on year.」
Cumulative nine-month sales of hemodialysis-related products were ¥4,824,126 thousand, accounting for approximately 37.4% of consolidated net sales of ¥12,894,503 thousand, confirming continued concentration of sales in this product group. - FY2017-Q2RestatedAnnual report
「Sales of hemodialysis-related products amounted to ¥3,148,193 thousand, up 9.5% year on year.」
Cumulative first-half sales of hemodialysis-related products were ¥3,148,193 thousand, accounting for approximately 37.5% of consolidated net sales of ¥8,389,011 thousand, confirming continued concentration of sales in this product group. - FY2017-Q1RestatedAnnual report
「Sales of hemodialysis-related products amounted to ¥1,581,334 thousand, up 12.9% year on year.」
First-quarter sales of hemodialysis-related products were ¥1,581,334 thousand, accounting for approximately 37.8% of consolidated net sales of ¥4,181,047 thousand. Although this is a single-quarter figure, continued concentration of sales in this product group can be confirmed. - FY2016First statedAnnual report
「Sales of hemodialysis-related products, centered on the core Happy Cass product, remained high in the fiscal year ended March 2016, at ¥5,761,588 thousand, accounting for 36.6% of consolidated net sales.」
The dependence risk has been quantified, with hemodialysis-related products accounting for 36.6% of consolidated net sales.